BiotechTube

Donepezil

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Postoperative Complications

Conditions

Postoperative Complications, Delirium

Trial Timeline

Feb 1, 2005 → Apr 1, 2007

NCT ID
NCT00182845

About Donepezil

Donepezil is a approved stage product being developed by Pfizer for Postoperative Complications. The current trial status is completed. This product is registered under clinical trial identifier NCT00182845. Target conditions include Postoperative Complications, Delirium.

What happened to similar drugs?

10 of 20 similar drugs in Postoperative Complications were approved

Approved (10) Terminated (1) Active (10)
✅Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVEisaiApproved
🔄SHR0410 Injection + SHR0410 Injection + PlaceboJiangsu Hengrui MedicinePhase 3
✅EsomeprazoleAstraZenecaApproved
🔄MK0966, rofecoxib + Comparator: valdecoxibMerckPhase 3
✅Aprepitant, Dexamethasone, Ondansetron + Aprepitant, Dexamethasone, PlaceboMerckApproved
✅Sugammadex + NeostigmineMerckApproved
🔄MK0869, aprepitant + Comparator: ondansetron IVMerckPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT00174382Phase 3Terminated
NCT00182845ApprovedCompleted
NCT00196690ApprovedCompleted

Competing Products

20 competing products in Postoperative Complications

See all competitors
ProductCompanyStageHype Score
Naldemedine + PlaceboShionogiPhase 2
27
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVEisaiApproved
43
Lemborexant 5 mg + Control (placebo) groupEisaiPhase 2
42
Ondansetron + PalonosetronEisaiPhase 2
35
AQUAVAN (fospropofol disodium; GPI 15715 )EisaiPhase 2
35
ONO-1101Ono PharmaceuticalPhase 2
35
ONO-1101Ono PharmaceuticalPhase 2/3
38
Levofloxacin Ophthalmic + CefuroximeSanten PharmaceuticalPhase 1/2
28
Levofloxacin Ophthalmic Product + Moxifloxacin Ophthalmic SolutionSanten PharmaceuticalPhase 1/2
28
Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparationJiangsu Hengrui MedicinePhase 1
29
SHR0410 Injection + SHR0410 Injection + PlaceboJiangsu Hengrui MedicinePhase 3
36
SHR8554 InjectionJiangsu Hengrui MedicinePhase 1
29
EsomeprazoleAstraZenecaApproved
43
deep neuromuscular blockMerckPre-clinical
26
Rolapitant Dose 1 + Rolapitant Dose 2 + Rolapitant Dose 3 + Rolapitant Dose 4 + Ondansetron + PlaceboMerckPhase 2
35
MK0966, rofecoxib + Comparator: valdecoxibMerckPhase 3
40
Aprepitant, Dexamethasone, Ondansetron + Aprepitant, Dexamethasone, PlaceboMerckApproved
43
MK0719MerckPhase 2
27
Sugammadex + NeostigmineMerckApproved
43
MK0869, aprepitant + Comparator: ondansetron IVMerckPhase 3
40